Position in GUTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$9,146
-$111,656 QoQ
Shares Held
19,971
-63.6% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Verition Fund Management LLC holds $147,085,063 across 39 Biotechnology names. GUTS ranks #39 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
802,293 | $42,296,886 | |
| 2 | ACLX |
Arcellx, Inc.
|
187,354 | $21,511,986 | |
| 3 | APLS |
Apellis Pharmaceuticals, Inc.
|
400,000 | $16,092,000 | |
| 4 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,000,000 | $14,460,000 | |
| 5 | EVMN |
Evommune, Inc.
|
549,991 | $12,644,293 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
110,000 | $10,697,500 | |
| 7 | OCUL |
Ocular Therapeutix, Inc
|
527,338 | $4,466,552 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
55,000 | $3,198,250 |
All Filings in GUTS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,146 | 19,971 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $120,802 | 54,910 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||